Loading
Life sciences · Journal article
Microorganisms · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Syndromic testing, defined as the simultaneous nucleic acid amplification-based detection of multiple potential pathogens and antimicrobial resistance (AMR) determinants directly from clinical specimens, has transformed laboratory diagnosis of infectious diseases in the United States over the past two decades. In contrast to traditional microbiology workflows that rely on culture, phenotypic susceptibility testing, and sequential single-target assays with turnaround times of 24–72 h or longer, syndromic multiplex panels provide comprehensive pathogen identification within 1–5 h, enabling timely clinical decision-making, targeted antimicrobial therapy, and improved patient outcomes. In this review, the current landscape of FDA-cleared syndromic testing panels across seven major clinical syndromes is examined, including respiratory tract infections, pneumonia, bloodstream infections, gastrointestinal infections, meningitis/encephalitis, joint and bone infections, and global febrile/travel-related illnesses. For each syndrome, commercially available panels in the United States are summarized, with emphasis on diagnostic performance, clinical applications, and limitations. Available evidence demonstrates that syndromic testing, when integrated with institutional diagnostic and antimicrobial stewardship programs, can reduce time to optimal therapy and unnecessary antimicrobial use and, in selected settings, shorten hospital length of stay. A mortality benefit has been reported in some patient populations, particularly those with bloodstream infections. Nevertheless, rapid turnaround time and earlier pathogen identification do not necessarily translate into timely clinical action and improved patient outcomes. Challenges related to implementation and optimization of appropriate panel utilization, including evolving AMR epidemiology, dynamic and geographically variable pathogen distributions, the critical role of diagnostic and antimicrobial stewardship, and emerging developments for diagnosis and management of infectious disease, are also discussed.